Mineralys Therapeutics IncNASDAQ:MLYS
- LAST PRICE12.4900
- TODAY'S CHANGE (%)0.6200 (5.2233%)
- Bid / Lots12.2600/ 1
- Ask / Lots13.1500/ 1
- Open / Previous Close11.8900 / 11.8700
- Day Range
- 52 Week Range
- Volume150,706
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MLYS |
|---|---|---|
| 09:32 ET | 3754 | 12.07 |
| 09:55 ET | 880 | 12.05 |
| 09:57 ET | 100 | 12.05 |
| 10:02 ET | 700 | 11.95 |
| 10:04 ET | 1577 | 12.01 |
| 10:08 ET | 100 | 11.94 |
| 10:20 ET | 100 | 11.96 |
| 10:31 ET | 100 | 11.86 |
| 10:33 ET | 263 | 11.843 |
| 10:36 ET | 428 | 11.87 |
| 10:38 ET | 100 | 11.88 |
| 10:42 ET | 233 | 11.92 |
| 10:44 ET | 400 | 11.94 |
| 10:45 ET | 200 | 11.94 |
| 10:47 ET | 1170 | 11.99 |
| 10:49 ET | 100 | 12.03 |
| 10:51 ET | 600 | 12.035 |
| 10:54 ET | 100 | 12.04 |
| 10:56 ET | 1334 | 11.98 |
| 10:58 ET | 1100 | 12 |
| 11:05 ET | 200 | 12.03 |
| 11:09 ET | 100 | 12.03 |
| 11:14 ET | 400 | 12.03 |
| 11:16 ET | 600 | 12.03 |
| 11:20 ET | 100 | 12.03 |
| 11:23 ET | 100 | 12.03 |
| 11:25 ET | 500 | 12.035 |
| 11:27 ET | 200 | 12.02 |
| 11:34 ET | 610 | 12.005 |
| 11:36 ET | 100 | 12 |
| 11:38 ET | 100 | 12.03 |
| 11:41 ET | 200 | 12.03 |
| 11:45 ET | 700 | 12.03 |
| 11:50 ET | 1668 | 12.05 |
| 11:52 ET | 200 | 12.09 |
| 11:54 ET | 100 | 12.09 |
| 11:57 ET | 15000 | 12.105 |
| 11:59 ET | 1340 | 12.24 |
| 12:01 ET | 100 | 12.27 |
| 12:06 ET | 100 | 12.27 |
| 12:08 ET | 462 | 12.205 |
| 12:10 ET | 575 | 12.27 |
| 12:14 ET | 100 | 12.27 |
| 12:15 ET | 705 | 12.27 |
| 12:19 ET | 100 | 12.335 |
| 12:21 ET | 300 | 12.39 |
| 12:24 ET | 200 | 12.335 |
| 12:26 ET | 100 | 12.39 |
| 12:30 ET | 700 | 12.37 |
| 12:32 ET | 811 | 12.27 |
| 12:33 ET | 800 | 12.27 |
| 12:44 ET | 200 | 12.29 |
| 12:46 ET | 400 | 12.32 |
| 12:51 ET | 464 | 12.39 |
| 12:55 ET | 100 | 12.375 |
| 01:02 ET | 100 | 12.41 |
| 01:06 ET | 100 | 12.41 |
| 01:08 ET | 100 | 12.375 |
| 01:09 ET | 100 | 12.41 |
| 01:13 ET | 200 | 12.48 |
| 01:15 ET | 400 | 12.445 |
| 01:20 ET | 200 | 12.455 |
| 01:24 ET | 200 | 12.49 |
| 01:26 ET | 100 | 12.485 |
| 01:27 ET | 200 | 12.46 |
| 01:29 ET | 100 | 12.49 |
| 01:31 ET | 100 | 12.49 |
| 01:33 ET | 580 | 12.49 |
| 01:36 ET | 100 | 12.5 |
| 01:38 ET | 2395 | 12.43 |
| 01:42 ET | 100 | 12.435 |
| 01:44 ET | 100 | 12.435 |
| 01:45 ET | 1481 | 12.36 |
| 01:47 ET | 100 | 12.39 |
| 01:49 ET | 200 | 12.36 |
| 01:51 ET | 100 | 12.39 |
| 01:54 ET | 100 | 12.38 |
| 01:56 ET | 100 | 12.35 |
| 01:58 ET | 596 | 12.36 |
| 02:00 ET | 100 | 12.36 |
| 02:02 ET | 200 | 12.39 |
| 02:03 ET | 1400 | 12.32 |
| 02:05 ET | 500 | 12.265 |
| 02:07 ET | 460 | 12.265 |
| 02:12 ET | 320 | 12.35 |
| 02:16 ET | 100 | 12.355 |
| 02:20 ET | 100 | 12.345 |
| 02:21 ET | 400 | 12.38 |
| 02:23 ET | 500 | 12.415 |
| 02:25 ET | 200 | 12.45 |
| 02:27 ET | 760 | 12.45 |
| 02:30 ET | 1300 | 12.45 |
| 02:32 ET | 1000 | 12.45 |
| 02:34 ET | 200 | 12.48 |
| 02:36 ET | 100 | 12.49 |
| 02:38 ET | 100 | 12.51 |
| 02:39 ET | 1003 | 12.5 |
| 02:45 ET | 100 | 12.53 |
| 02:48 ET | 820 | 12.53 |
| 02:52 ET | 2886 | 12.54 |
| 02:54 ET | 500 | 12.495 |
| 02:57 ET | 1240 | 12.57 |
| 02:59 ET | 700 | 12.58 |
| 03:01 ET | 801 | 12.55 |
| 03:03 ET | 400 | 12.475 |
| 03:06 ET | 592 | 12.433 |
| 03:08 ET | 100 | 12.46 |
| 03:14 ET | 1200 | 12.435 |
| 03:17 ET | 400 | 12.47 |
| 03:19 ET | 100 | 12.45 |
| 03:21 ET | 400 | 12.41 |
| 03:26 ET | 100 | 12.4 |
| 03:28 ET | 200 | 12.44 |
| 03:30 ET | 200 | 12.42 |
| 03:35 ET | 100 | 12.44 |
| 03:37 ET | 300 | 12.425 |
| 03:39 ET | 700 | 12.5 |
| 03:42 ET | 200 | 12.5 |
| 03:44 ET | 400 | 12.48 |
| 03:46 ET | 1238 | 12.44 |
| 03:48 ET | 700 | 12.47 |
| 03:50 ET | 400 | 12.5 |
| 03:51 ET | 2280 | 12.46 |
| 03:53 ET | 644 | 12.48 |
| 03:55 ET | 2315 | 12.51 |
| 03:57 ET | 1004 | 12.49 |
| 04:00 ET | 22515 | 12.49 |
Nov 12, 2024
DJ Mineralys Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 6:43AM ET on Tuesday Nov 12, 2024 by Dow Jones
6:43AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
4:05PM ET on Monday Nov 11, 2024 by Dow JonesPress Release: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
4:05PM ET on Monday Nov 11, 2024 by Dow Jones
Nov 5, 2024
Mineralys Therapeutics to Participate in Upcoming Investor Conferences, from 4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mineralys Therapeutics Inc | 590.3M | -3.8x | --- |
Tourmaline Bio Inc | 582.6M | -13.7x | --- |
Altimmune Inc | 597.4M | -5.6x | --- |
Dianthus Therapeutics Inc | 599.9M | -9.0x | --- |
Corvus Pharmaceuticals Inc | 559.2M | -9.7x | --- |
Savara Inc | 556.0M | -7.5x | --- |
Company Information
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Contact Information
- Headquarters
- 150 N. Radnor Chester Road, Suite F200RADNOR, PA, United States 19087
- Phone
- 302-658-7581
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Founder
- Brian Slingsby
- Chief Executive Officer, Director
- Jon Congleton
- Chief Financial Officer, Company Secretary
- Adam Levy
- Chief Medical Officer
- David Rodman
- Chief Business Officer
- Minji Kim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $590.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.27 |
Book Value | $5.86 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
